AACR 2024: Adagrasib plus cetuximab may provide clinical benefit in patients with KRASG12c-mutated colorectal cancer
A combination of the KRASG12C inhibitor adagrasib and the anti-epidermal growth factor receptor (EGFR) antibody…
Browsing: EGFR
Treatment of advanced non-small cell lung cancer with driver mutations
Lung cancer is the leading cause of cancer-related death worldwide. Improved understanding of driver mutations…
Newly discovered link between FBXW7 mutations and EGFR signalling in colorectal cancer
The Organoid group at the Hubrecht Institute have identified a new link between FBXW7 mutations and…
FDA approves amivantamab-vmjw for EGFR exon 20 insertion-mutated non-small cell lung cancer indications
On March 1, 2024, the Food and Drug Administration approved amivantamab-vmjw with carboplatin and pemetrexed…
Study proposes streamlined approach to developing cancer drugs
Drug discovery can be a frustrating process of trial and error. Scientists using fragment-based drug…
Lung cancer hijacks immune cell metabolism to fuel its own growth
There are several ways lung adenocarcinoma can arise, one of which is a mutation in…
Amivantamab plus chemo with or without lazertinib reduced risk of disease progression or death for EGFR-mutated NSCLC
The results from the Phase 3 MARIPOSA study were announced showing amivantamab-vmjw in combination with…
ESMO 2023: Amivantamab plus chemo with or without lazertinib reduced risk of disease progression or death for EGFR-mutated NSCLC
The results from the Phase 3 MARIPOSA-2 study have been announced showing the regimen of…
Suppression of cancer stemness and drug resistance via BRAF/EGFR/MEK inhibition in colorectal cancer cells
A new research paper was published in Oncotarget’s Volume 14 on October 4, 2023, entitled, “Inhibiting BRAF/EGFR/MEK suppresses…
WCLC 2023: Osimertinib plus chemotherapy demonstrated superior results than osimertinib alone for patients with EGFR-mutated advanced lung cancer
Osimertinib plus chemotherapy demonstrated a statistically significant and clinically meaningful progression-free survival benefit compared to…